Healthiosxchange to Capitalize on New Crowdfunding Flexibility
Despite a flood of capital into biotech initial public offerings and breathtaking market runs, venture capital (VC) is still shunning many early stage life science companies. According to a May MoneyTree report by PwC and the National Venture Capital Association, VC investment in biotechnology and medical device firms dropped in value and volume during the first quarter of 2013 as investors turned to less capital-intensive industries.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST